Open Access
How to translate text using browser tools
1 January 2020 Colonic malignant peripheral nerve sheath tumour in a cat
Lara Boland, Laura Setyo, Cheryl Sangster, Laurencie Brunel, Timothy Foo, Peter Bennett
Author Affiliations +
Abstract

Case summary

A 14-year-old male neutered domestic mediumhair cat presented with a 4 month history of inappetence and weight loss. Pertinent abnormalities on haematology and biochemistry included a mild microcytic regenerative anaemia (packed cell volume [PCV] 24% [reference interval (RI) 30–45%], mean cell volume 30.8 fl [RI 40–45 fl], absolute reticulocyte count 326.8 × 1012) and increased alkaline phosphatase activity (76 IU/l; RI <50 IU/l). Abdominal ultrasound and CT scan revealed masses in the transverse colon (2.0 cm × 1.2 cm) and right medial liver lobe (5.0 cm diameter). Thoracic radiographs were unremarkable. Right medial liver lobe resection and colectomy were performed. Immunohistochemistry was positive for S-100 protein, vimentin and glial fibrillary acidic protein, very weakly positive for c-kit and negative for muscle-specific actin and CD18, consistent with a colonic malignant peripheral nerve sheath tumour (MPNST) with a hepatic metastasis. Postoperative treatment with metronomic cyclophosphamide was well tolerated. Eighteen months postoperatively the cat re-presented after 3 days of progressive lethargy and inappetence. Haematology revealed a marked non- or pre-regenerative anaemia (PCV 10%). Coagulation times were prolonged (prothrombin time 39 s [RI 15–22 s] and activated partial thromboplastin time >300 s [RI 65–119 s]). Abdominal ultrasound identified multiple renal and hepatic nodules. Euthanasia was performed and post-mortem examination confirmed metastasis of the MPNST.

Relevance and novel information

This report describes the treatment of a metastatic colonic peripheral nerve sheath tumour in a cat. Feline visceral MPNSTs are rare and little is known about prognosis or optimal treatment.

Introduction

Peripheral nerve sheath tumours (PNSTs) are neoplasms originating from Schwann cells, perineural cells and intraneural fibroblasts. Sub-classifications are used in human medicine (eg, Schwannoma, neurofibroma); however, owing to unclear histiogenesis, in veterinary medicine they are usually divided into benign or malignant (MPNST).123 Feline PNSTs are uncommonly reported, usually occur in older cats, are mostly benign and usually involve the skin/subcutis of the head, neck and limbs.1,4567891011 MPNSTs involving the spinal cord/canal are uncommonly reported and rarely reported sites include the gingiva, eye, small intestine and bladder, or are perirenal.121314151617181920 Approximately 15% of benign and 30% of malignant feline dermal/subcutaneous PNSTs recur locally.1 Metastatic disease is rarely reported.17 Surgical resection may be curative; however, there are few reports of postoperative follow-up or treatment of incompletely resected or metastatic feline MPNSTs.1,121314,17,21 Strontium plesiotherapy following marginal resection of feline eyelid MPNSTs has been described.21

This report describes the presentation, diagnosis, treatment and outcome of a colonic MPNST with hepatic metastasis in a cat. To our knowledge, this is the second case report of an intestinal MPNST and the second of PNST metastases in a cat.12,17

Case description

A 14-year-old male neutered domestic mediumhair cat was referred for investigation of 4 months of inappetence and 1.2 kg weight loss. Diabetes mellitus had been diagnosed 2 years earlier and was well managed with insulin glargine (Lantus; Sanofi) with doses up to 4 IU subcutaneously (SC) q12h and a high-protein/low-carbohydrate diet (Hill’s m/d; Hill’s Pet Nutrition). In the month prior to referral the insulin dose had been reduced to 2 IU SC q12h based on blood glucose curves.

Physical examination revealed a low body condition score (3/9) and a grade II/VI left systolic cardiac murmur. Pertinent abnormalities on haematology and biochemistry included a mild microcytic regenerative anaemia (packed cell volume [PCV] 24% [reference interval (RI) 30–45%], mean cell volume 30.8 fl [RI 40–45 fl], absolute reticulocyte count 326.8 × 1012), mild neutrophilia (15.35 × 109/l; RI 3.76–10.08 × 109/l) and increased alkaline phosphatase activity (76 IU/l; RI <50 IU/l). Urinalysis was unremarkable.

Abnormalities identified on abdominal ultrasound included a 5.0 cm diameter, large, heterogeneous and poorly vascularised mass within the right medial lobe of the liver, which was fluid-filled centrally (Figure 1), and an eccentrically located, intramural (2.0 cm × 1.4 cm) hypoechoic mass within the distal portion of the transverse colon with loss of normal wall layering (Figure 2). Thoracic radiographs were unremarkable.

Figure 1

Transverse sonogram (Phillips EPIQ5; Phillips Medical Systems) of the right medial liver lobe. There was a large, heterogeneous mass (outlined by callipers) containing a central fluid-filled component

10.1177_2055116919849979-fig1.tif

Figure 2

Longitudinal sonogram of the transverse colon. There was an eccentric, intramural hypoechoic mass within the distal portion of the transverse colon. Note the displacement of the intraluminal gas interface by this lesion (arrows)

10.1177_2055116919849979-fig2.tif

Fine-needle aspirate cytology of the masses was non-diagnostic. Coagulation times were within the RIs. The cardiac murmur was not investigated owing to financial constraints. Colonoscopy revealed a smooth, raised mass in the transverse colon and biopsies were collected (Figure 3). An ultrasound-guided liver mass biopsy (Vet-Core biopsy needle 16 G 9 cm; Smiths Medical USA) was performed and an oesophageal feeding tube was placed.

Figure 3

Colonoscopy revealed a smooth, raised mass in the transverse colon

10.1177_2055116919849979-fig3.tif

Histopathology of the colonic and hepatic masses revealed disorganised large pale pleomorphic spindle cells with prominent nucleoli. The colonic mass was suspected to be a primary spindle cell sarcoma with the liver mass representing a metastasis.

Pre- and post-contrast enhanced CT of the abdomen was performed for tumour staging and surgical planning. A heterogeneous soft tissue-attenuating 4.3 cm mass was noted within the right medial lobe of the liver (Figure 4). This mass was heterogeneously enhancing post-contrast administration with multiple, coalescing non-contrast-enhancing areas suggestive of necrosis. Within the transverse colon, there was a hypoattenuating mass (2.4 cm × 1.4 cm × 0.6 cm) with heterogeneous, predominantly peripheral enhancement post-contrast administration (Figure 5).

Figure 4

CT images of the (a) transverse and (b) dorsal planes of the abdomen displayed in a soft tissue window. The patient’s right is to the left. There was a large heterogeneous hepatic mass within the right medial lobe (arrows). Note the heterogeneous post-contrast enhancement of the mass with multiple coalescing non-enhancing regions suggestive of necrosis. Images obtained with a 16-detector row CT scanner (Phillips 16-slice Brilliance CT V2.3; Phillips Medical Systems [120 kVp, 100 mAs, 1.5 mm slice thickness])

10.1177_2055116919849979-fig4.tif

Figure 5

CT images of the (a) transverse and (b) dorsal planes of the abdomen displayed in a soft tissue window. The patient’s right is to the left. There is an intramural hypoechoic mass within the transverse colon (arrows). Note the heterogeneous, predominantly peripheral contrast enhancement of the mass.

10.1177_2055116919849979-fig5.tif

Laparotomy was performed under general anaesthesia. The hepatic mass was separated from the gall bladder by blunt dissection and right medial and quadrate liver lobe resection performed because of shared vasculature (Figure 6). The rest of the liver had a diffusely mottled appearance and a 6 mm punch biopsy was collected from the left medial lobe. The colonic mass was identified at the hepatic flexure of the colon and removed by colectomy and anastomosis. Postoperative analgesia was provided by a fentanyl continuous rate infusion (5 µg/kg/h for 48 h) followed by buprenorphine (0.015 mg/kg IV q8h for 24h) and then 0.02 mg/kg sublingually for another 48 h.

Figure 6

Intraoperative image of the right medial liver lobe mass (arrow) adjacent to the gall bladder

10.1177_2055116919849979-fig6.tif

The feeding tube was removed after 2 weeks. Postoperative medications included: amoxicillin-clavulanate (Augmentin; GlaxoSmithKline) 20 mg/kg intravenously (IV) q8h for 48 h then orally (PO) for 7 days; metronidazole (Metronidazole Sandoz IV; Sandoz) 10 mg/kg IV q12h for 48 h then PO for 7 days; enrofloxacin (Baytril; Bayer) 2.5 mg/kg SC q12h for 48 h then PO for 7 days; maropitant (Cerenia; Zoetis) 1 mg/kg SC q24h for 48 h then PO for 5 days; and insulin glargine 1 IU SC q12h.

Histopathology of the colonic mass (Figure 7) revealed a poorly circumscribed, unencapsulated, well-demarcated, densely cellular, infiltrative neoplasm composed of spindle cells arranged in interlacing streams and bundles separated by a scant eosinophilic fibrillary matrix that was transmurally infiltrating and effacing the mucosa, lamina propria, submucosa, tunica muscularis and serosa, and extending into the colonic lumen. Neoplastic cells had variably distinct cell borders, moderate-to-abundant eosinophilic fibrillar cytoplasm, oval-to-elongated nuclei containing finely stippled chromatin and generally one distinct nucleolus. The mitotic rate averaged one per 10 high-powered fields. There was marked anisocytosis and anisokaryosis. In addition, there was scattered necrosis and lymphoplasmacytic aggregates. The mass appeared to have been completely excised. Similar neoplastic infiltrates admixed with scattered single-cell necrosis infiltrated and replaced the architecture of the right medial liver lobe (Figure 8).

Figure 7

Colonic mass. Neoplastic cells are arranged in interlacing streams and bundles. Haematoxylin and eosin (× 400)

10.1177_2055116919849979-fig7.tif

Figure 8

Hepatic mass. Neoplastic cells demonstrate similar behaviour to the colonic mass (Figure 7). Note the marked anisocytosis and anisokaryosis. Haematoxylin and eosin (× 400)

10.1177_2055116919849979-fig8.tif

The cat was diagnosed with a colonic malignant spindle-cell neoplasm with hepatic metastasis. Immuno-histochemistry revealed that both masses stained positive for S-100 protein, vimentin and glial fibrillary acidic protein, very weakly positive for c-kit and negative for muscle-specific actin and CD18, consistent with a diagnosis of a MPNST (Figures 9Figure 10Figure 1112).1,8,222324

Figure 9

Colonic mass. Neoplastic cells demonstrate diffuse marked nuclear and cytoplasmic labelling for S-100. Peroxidase immunohistochemistry and haematoxylin and eosin (× 400)

10.1177_2055116919849979-fig9.tif

Figure 10

Colonic mass. Neoplastic cells demonstrate diffuse marked cytoplasmic labelling for vimentin. Peroxidase immunohistochemistry and haematoxylin and eosin (× 400)

10.1177_2055116919849979-fig10.tif

Figure 11

Hepatic mass. Neoplastic cells demonstrate diffuse marked cytoplasmic labelling for glial fibrillary acidic protein. Peroxidase immunohistochemistry and haematoxylin and eosin (× 400)

10.1177_2055116919849979-fig11.tif

Figure 12

Colonic mass. Neoplastic cells demonstrate scattered faintly positive cytoplasmic labelling for c-kit. Peroxidase immunohistochemistry and haematoxylin and eosin (× 400)

10.1177_2055116919849979-fig12.tif

Metronomic chemotherapy was commenced 2 weeks postoperatively with cyclophosphamide 15.5 mg/m2 PO q24h. Cyclophosphamide was well tolerated long term. Intermittent vomiting occurred and was treated with maropitant 1.5 mg/kg PO q24h and omeprazole (Losec; AstraZeneca) 1.5 mg/kg PO q24h as required. Haema-tology performed at 1, 2, 3 and 5 months revealed microcytosis for 3 months before resolution. Insulin glargine was increased to 3 IU SC q12h by 5 months postoperatively, based on blood glucose curves performed every 1–2 months. The cat gained 200 g following surgery and maintained a stable body weight.

Sixteen months postoperatively, the cat was re-presented to the referring veterinarian for polyuria and polydipsia. Fructosamine indicated over-control of diabetes mellitus (203 µmol/l; RI 221–340 µmol/l), hyperthyroidism was diagnosed (total thyroxine 92 nmol/l; RI 10–60 nmol/l), and pertinent abnormalities on haematology and biochemistry included a mild anaemia (haematocrit 24%; RI 30–52%) and increased alanine aminotransferase activity (138 IU/l; RI 12–130 IU/l). The insulin dose was reduced to 2 IU SC q12h and methimazole transdermal gel 5 mg q12h was commenced.

Eighteen months postoperatively the cat re-presented following 3 days of progressive lethargy and inappetence. Physical examination revealed 100 g of weight loss, marked lethargy, pallor, a right-sided goitre and a grade II/VI left systolic cardiac murmur. Haematology revealed a marked non- or pre-regenerative anaemia (PCV 10%). Coagulation times were prolonged (prothrombin time 39 s [RI 15–22 s] and activated partial thromboplastin time >300 s [RI 65–119 s]). Abdominal ultrasound identified multiple renal and hepatic nodules ( Figure 13 in the  supplementary material). Thoracic radiographs were unremarkable. Retroviral testing was negative (Witness FIV-FeLV; Zoetis). The owner elected euthanasia. Post-mortem examination, including renal immunohistochemistry, confirmed the presence of an MPNST within the kidneys and liver ( Figures 14–21 in the  supplementary material). Additional findings of note observed incidentally on gross and microscopic post-mortem examination included thyroid cystic follicular adenomas, cardiac fibrosis and islet amyloidosis.

Discussion

Ribas et al reported a small intestinal MPNST, without metastasis, in a cat that was treated with surgical resection and that was clinically well 6 months postoperatively.12 Buza et al reported a partially resected gingival MPNST in a cat that developed local recurrence and post-mortem examination identified nodal and pulmonary metastases after an 8.5 month survival time.17 Pavia et al described a urinary bladder MPNST in a cat that died several weeks after partial cystectomy.13 The case reported here is unique in that the cat was treated with surgical resection of the primary tumour and hepatic metastasis, received postoperative metronomic chemotherapy and had a prolonged survival time.

MPNSTs in humans are rare and half occur in people with neurofibromatosis type 1, an autosomal dominant disorder.2,25,26 Treatment focuses on surgical resection with the role of postoperative radiation and chemotherapy less well defined.25

Most MPNST in dogs arise from spinal nerves and nerve roots of the brachial plexus or, less commonly, from the trigeminal nerve or skin.21,27,28 Rarely reported sites of origin include the lung, spleen, liver, diaphragm, vagus nerve, tongue, omentum, ocular origin, heart, brain, adrenal gland and testis.22,29303132333435363738394041424344454647484950 Incomplete surgical resection leads to recurrence and metastatic disease is rarely reported.22,24,39,43,44,46,47,49505152 Stereotactic radiation therapy for canine trigeminal and brachial plexus MPNSTs may prolong survival times when surgical resection is not possible.28,53 Metronomic cyclophosphamide and piroxicam treatment delays recurrence in dogs with incompletely resected MPNST.49,54 Cryosurgery of small canine dermal MPNSTs has been reported.55 Immunotherapy with interleukin-2 following marginal surgical resection did not prolong survival times in dogs.52

The major initial differential diagnoses in the case reported here were a leiomyosarcoma or gastrointestinal stromal cell tumour (GIST), which are uncommon to rare in cats, respectively.56,57 The immunohistochemistry was consistent with a PNST, which are usually S-100 protein and vimentin positive, muscle-specific actin negative and most are glial fibrially acidic protein positive.1 The neoplasm also stained weakly positive for c-kit; however, a GIST was excluded given the positive S-100 protein and the unconvincing nature of the c-kit staining.57

The colonic mass was presumed to be the primary tumour with hepatic metastasis. Given that surgical resection was unlikely to be curative, metronomic cyclophosphamide was used. Conventional chemotherapy for feline MPNSTs has not been reported. Metronomic cyclophosphamide rather than intravenous doxorubicin was chosen owing to financial constraints, potential side effects and stress to the cat, along with a lack of information on efficacy for either doxorubicin or metronomic chemotherapy. Use of metronomic cyclophosphamide for various feline tumour types, including soft tissue sarcomas, has been reported and well tolerated; however, there is scarce information about tumour response rates.58 Conclusions cannot be drawn about what impact metronomic chemotherapy had on the survival time of this cat.

The prognostic significance of distant metastases at the time of diagnosis is unclear for cats with MPNSTs owing to limited publications. Resection of both GIST and non-GIST sarcoma hepatic metastases in selected human patients is associated with improved survival times.59,60 Similar data are not available for companion animals and conclusions cannot be drawn about what impact the hepatic mass resection had on the survival time of this cat.

Conclusions

Visceral MPNSTs are rarely reported in cats and little is known about prognosis or optimal treatment. This report describes a colonic MPNST with hepatic metastasis that was treated with surgical resection and metronomic cyclophosphamide. An 18 month survival time was achieved before the development of clinically significant disease secondary to tumour recurrence.

Supplemental Material

Supplementary_material – Supplemental material for Colonic malignant peripheral nerve sheath tumour in a cat

Supplemental material, Supplementary_material for Colonic malignant peripheral nerve sheath tumour in a cat by Lara Boland, Laura Setyo, Cheryl Sangster, Laurencie Brunel, Timothy Foo and Peter Bennett in Journal of Feline Medicine and Surgery Open Reports

Acknowledgements

The authors would like to thank the cat’s owner, staff and students of the Valentine Charlton Cat Centre, and Summer Hill Village Vet for provision of follow-up information.

References

1.

Schulman FY, Johnson TO, Facemire PRet al . Feline peripheral nerve sheath tumors: histologic, immunohistochemical, and clinicopathologic correlation (59 tumors in 53 cats). Vet Pathol 2009; 46: 1166–1180. Google Scholar

2.

Rodriguez FJ, Folpe AL, Giannini Cet al . Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 2012; 123: 295–319. Google Scholar

3.

Stoll A, Suárez-Bonnet A, Summers Bet al . Malignant cutaneous peripheral nerve sheath tumour with rhabdomyosarcomatous differentiation (Triton tumour) in a domestic cat. J Comp Pathol 2018; 165: 1–5. Google Scholar

4.

Hoffman A, Blocker T, Dubielzig Ret al . Feline periocular peripheral nerve sheath tumor: a case series. Vet Ophthalmol 2005; 8: 153–158. Google Scholar

5.

Newkirk KM, Rohrbach BW. A retrospective study of eyelid tumors from 43 cats. Vet Pathol 2009; 46: 916–927. Google Scholar

6.

Watrous BJ, Lipscomb TP, Heidel JRet al . Malignant peripheral nerve sheath tumor in a cat. Vet Radiol Ultrasound 1999; 40: 638–640. Google Scholar

7.

Jones B, Alley M, Johnstone Aet al . Nerve sheath tumours in the dog and cat. N Z Vet J 1995; 43: 190–196. Google Scholar

8.

Mandara MT, Fabriani E, Pavone Set al . Feline cutaneous nerve sheath tumours: histological features and immunohistochemical evaluations. Res Vet Sci 2013; 95: 548–555. Google Scholar

9.

de Cecco BS, da Silva TM, Felin DVet al . Malignant peripheral nerve sheath tumor in a cat: cytological, histopathological, and immunohistochemical aspects. Comp Clin Path 2018; 27: 803–806. Google Scholar

10.

Tremblay N, Lanevschi A, Doré Met al . Of all the nerve! A subcutaneous forelimb mass on a cat. Vet Clin Pathol 2005; 34: 417–420. Google Scholar

11.

Dillon CJ, Mauldin GN, Baer KE. Outcome following surgical removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992–2000). J Am Vet Med Assoc 2005; 227: 1955–1957. Google Scholar

12.

Ribas A, Miller R, Rasotto R . Small intestinal peripheral nerve sheath tumour in a cat. JFMS Open Rep 2017; 3 https://doi.org/ https://doi.org/10.1177/2055116917710394Google Scholar

13.

Pavia P, Havig M, Donovan Tet al . Malignant peripheral nerve sheath tumour of the urinary bladder in a cat. J Small Anim Pract 2012; 53: 245–248. Google Scholar

14.

Okada M, Kitagawa M, Shibuya Het al . Malignant peripheral nerve sheath tumor arising from the spinal canal in a cat. J Vet Med Sci 2007; 69: 683–686. Google Scholar

15.

Stoica G, Tasca S, Kim H-T . Point mutation of neu oncogene in animal peripheral nerve sheath tumors. Vet Pathol 2001; 38: 679–688. Google Scholar

16.

Boonsriroj H, Kimitsuki K, Akagi Tet al . Malignant epithelioid schwannoma of the oral cavity in a cat. J Vet Med Sci 2014; 76: 927–930. Google Scholar

17.

Buza EL, Menzies RA, Goldschmidt MHet al . Malignant peripheral nerve sheath tumor in a cat with nodal and pulmonary metastases. J Vet Diagn Invest 2012; 24: 781–784. Google Scholar

18.

Evans PM, Lynch GL, Dubielzig RR . Anterior uveal spindle cell tumor in a cat. Vet Ophthalmol 2010; 13: 387–390. Google Scholar

19.

Marioni-Henry K, Van Winkle TJ, Smith SHet al . Tumors affecting the spinal cord of cats: 85 cases (1980–2005). J Am Vet Med Assoc 2008; 232: 237–243. Google Scholar

20.

Rossmeisl JH, Jr, Lanz O, Waldron Det al . Surgical cytoreduction for the treatment of non-lymphoid vertebral and spinal cord neoplasms in cats: retrospective evaluation of 26 cases (1990–2005). Vet Comp Oncol 2006; 4: 41–50. Google Scholar

21.

Berlato D, Serras AR, Riera MMet al . Marginal resection and adjuvant strontium plesiotherapy in the management of feline eyelid malignant peripheral nerve sheath tumours: two cases. JFMS Open Rep 2016; 2 https://doi.org/ https://doi.org/10.1177/2055116916674863Google Scholar

22.

Suzuki S, Uchida K, Nakayama H . The effects of tumor location on diagnostic criteria for canine malignant peripheral nerve sheath tumors (MPNSTs) and the markers for distinction between canine MPNSTs and canine perivascular wall tumors. Vet Pathol 2014; 51: 722–736. Google Scholar

23.

Sirri R, Sabattini S, Bettini Get al . Reclassification of 21 presumptive canine peripheral nerve sheath tumors (PNST) using a literature-based immunohistochemical panel. Acta Vet 2016; 66: 455–465. Google Scholar

24.

Chijiwa K, Uchida K, Tateyama S . Immunohistochemical evaluation of canine peripheral nerve sheath tumors and other soft tissue sarcomas. Vet Pathol 2004; 41: 307–318. Google Scholar

25.

Kim A, Stewart DR, Reilly KMet al . Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma 2017; 2017 https://doi.org/ https://doi.org/10.1155/2017/7429697Google Scholar

26.

Agaimy A, Märkl B, Kitz Jet al . Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants. Virchows Arch 2010; 456: 411–422. Google Scholar

27.

Ko S-B, Song K-O, Kang S-Cet al . Cutaneous peripheral nerve sheath tumors in 15 dogs. Korean J Vet Res 2014; 54: 7–12. Google Scholar

28.

Swift KE, McGrath S, Nolan MWet al . Clinical and imaging findings, treatments, and outcomes in 27 dogs with imaging diagnosed trigeminal nerve sheath tumors: a multi-center study. Vet Radiol Ultrasound 2017; 58: 679–689. Google Scholar

29.

Silva E, Goiozo P, Pereira Let al . Concomitant malignant pulmonary peripheral nerve sheath tumour and benign cutaneous peripheral nerve sheath tumour in a dog. J Comp Pathol 2017; 157: 46–50. Google Scholar

30.

Bergmann W, Burgener I, Roccabianca Pet al . Primary splenic peripheral nerve sheath tumour in a dog. J Comp Pathol 2009; 141: 195–198. Google Scholar

31.

Park J-W, Woo G-H, Jee Het al . Malignant peripheral nerve sheath tumour in the liver of a dog. J Comp Pathol 2011; 144: 223–226. Google Scholar

32.

Patterson CC, Perry RL, Steficek B . Malignant peripheral nerve sheath tumor of the diaphragm in a dog. J Am Anim Hosp Assoc 2008; 44: 36–40. Google Scholar

33.

Anderson GM, Dallaire A, Miller LMet al . Peripheral nerve sheath tumor of the diaphragm with osseous differentiation in a one-year-old dog. J Am Anim Hosp Assoc 1999; 35: 319–322. Google Scholar

34.

Akdesir E . Malignant peripheral nerve sheath tumour in the tongue of a dog. J Comp Pathol 2012; 69: 243–246. Google Scholar

35.

Baratt RM, Rawlinson J, Roth-Johnson Let al . Lingual malignant peripheral nerve sheath tumor in a Chinese pug dog. J Vet Dent 2015; 32: 165–172. Google Scholar

36.

Yap F, Pratschke K . Peripheral nerve sheath tumor of the vagus nerve in a dog. J Am Anim Hosp Assoc 2016; 52: 57–62. Google Scholar

37.

Hara Y, Tagawa M, Ejima Het al . Regression of hypertrophic osteopathy following removal of intrathoracic neoplasia derived from vagus nerve in a dog. J Vet Med Sci 1995; 57: 133–135. Google Scholar

38.

Ruppert C, Hartmann K, Fischer Aet al . Cervical neoplasia originating from the vagus nerve in a dog. J Small Anim Pract 2000; 41: 119–122. Google Scholar

39.

So B, Jung J, Jung Jet al . Omental malignant peripheral nerve sheath tumour with pulmonary and hepatic metastasis in a dog. J Comp Pathol 2016; 1: 104. Google Scholar

40.

Leis ML, Salpeter ME, Bauer BSet al . Primary bilateral corneal nerve sheath neoplasm in a dog. Vet Ophthalmol 2017; 20: 365–371. Google Scholar

41.

Sugiyama A, Morita T, Shimada Aet al . Primary malignant peripheral nerve sheath tumor with eosinophilic cytoplasmic globules arising from the greater omentum in a dog. J Vet Med Sci 2008; 70: 739–742. Google Scholar

42.

Sato T, Yamamoto A, Shibuya Het al . Intraocular peripheral nerve sheath tumor in a dog. Vet Ophthalmol 2005; 8: 283–286. Google Scholar

43.

Duke FD, Brudenall DK, Scott EMet al . Metastatic uveal schwannoma of blue-eyed dogs. Vet Ophthalmol 2013; 16: 141–144. Google Scholar

44.

Zarfoss M, Klauss G, Newkirk Ket al . Uveal spindle cell tumor of blue-eyed dogs: an immunohistochemical study. Vet Pathol 2007; 44: 276–284. Google Scholar

45.

Wohlsein P, Cichowski S, Baumgärtner W . Primary endocardial malignant spindle-cell sarcoma in the right atrium of a dog resembling a malignant peripheral nerve sheath tumour. J Comp Pathol 2005; 132: 340–345. Google Scholar

46.

Shihab N, Summers BA, Benigni Let al . Imaging diagnosis – malignant peripheral nerve sheath tumor presenting as an intra-axial brain mass in a young dog. Vet Radiol Ultrasound 2013; 54: 278–282. Google Scholar

47.

vom Hagen F, Romkes G, Kershaw Oet al . Malignant peripheral nerve sheath tumor of the third eyelid in a 3-year-old Rhodesian Ridgeback. Clin Case Rep 2015; 3: 50–56. Google Scholar

48.

Rothwell T, Papadimitriou J, Xu F-Net al . Schwannoma in the testis of a dog. Vet Pathol 1986; 23: 629–631. Google Scholar

49.

Briffod C, Hélie P, De Lasalle Jet al . Case report. Can Vet J 2018; 59: 379–384. Google Scholar

50.

Ichikawa M, Suzuki S, Tei Met al . Malignant peripheral nerve sheath tumor originating from the adrenal gland in a dog. J Vet Med Sci 2018; 80: 1572–1575. Google Scholar

51.

Garcı́a P, Sanchez B, Sanchez Met al . Epithelioid malignant peripheral nerve sheath tumour in a dog. J Comp Pathol 2004; 131: 87–91. Google Scholar

52.

Haagsman AN, Witkamp AC, Sjollema BEet al . The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision. A double-blind randomized study. BMC Vet Res 2014; 9: 155. DOI: 10.1186/1746-6148-9-155. Google Scholar

53.

Dolera M, Malfassi L, Bianchi Cet al . Frameless stereotactic volumetric modulated arc radiotherapy of brachial plexus tumours in dogs: 10 cases. Br J Radiol 2016; 90 https://doi.org/ https://doi.org/10.1259/bjr.20160617Google Scholar

54.

Elmslie R, Glawe P, Dow S . Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008; 22: 1373–1379. Google Scholar

55.

De Queiroz GF, Matera JM, Zaidan Dagli ML . Clinical study of cryosurgery efficacy in the treatment of skin and subcutaneous tumors in dogs and cats. Vet Surg 2008; 37: 438–443. Google Scholar

56.

Rissetto K, Villamil JA, Selting KAet al . Recent trends in feline intestinal neoplasia: an epidemiologic study of 1,129 cases in the veterinary medical database from 1964 to 2004. J Am Anim Hosp Assoc 2011; 47: 28–36. Google Scholar

57.

Morini M, Gentilini F, Pietra Met al . Cytological, immunohistochemical and mutational analysis of a gastric gastrointestinal stromal tumour in a cat. J Comp Pathol 2011; 145: 152–157. Google Scholar

58.

Leo C, Stell A, Borrego Jet al . Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia. J Feline Med Surg 2014; 16: 671–678. Google Scholar

59.

Goumard C, Marcal LP, Wang W-Let al . Long-term survival according to histology and radiologic response to preoperative chemotherapy in 126 patients undergoing resection of non-GIST sarcoma liver metastases. Ann Surg Oncol 2018; 25: 107–116. Google Scholar

60.

DeMatteo RP, Shah A, Fong Yet al . Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540–547. Google Scholar

Notes

[1] Accepted: 11 April 2019

[2] Supplementary material The following files are available

Figure 13: Longitudinal sonogram of the right kidney 18 months postoperatively showing a rounded (7.3 mm long × 7.7 mm thick), heterogeneously hypoechoic nodule present in the caudal cortex of the right kidney.

Figure 14: Photograph of the right kidney upon post-mortem examination, with an off-white multilobulated irregular mass protruding from the kidney that extends through the cortex on section.

Figure 15: Photograph of the left kidney upon post-mortem examination, with a loss of reniform appearance, and blunting of the left cranial aspect by a smooth pale-tan focus.

Figure 16: Photograph of the liver upon post-mortem examination, with numerous pale-tan firm nodules peppered across the hepatic serosa.

Figure 17: Histopathology of the renal mass upon post-mortem examination, with neoplastic cells demonstrating similar behaviour to the colonic mass (Figure 7), and marked anisocytosis and anisokaryosis.

Figure 18: Immunohistochemistry of the renal mass upon post-mortem examination, with neoplastic cells demonstrating diffuse marked nuclear and cytoplasmic labelling for S-100.

Figure 19: Immunohistochemistry of the renal mass upon post-mortem examination, with neoplastic cells demonstrating diffuse marked cytoplasmic labelling for vimentin.

Figure 20: Immunohistochemsitry of the renal mass upon post-mortem examination, with neoplastic cells demonstrating scattered faintly positive cytoplasmic labelling for c-kit.

Figure 21: Immunohistochemistry of the renal mass upon post-mortem examination, with neoplastic cells demonstrating diffuse marked cytoplasmic labelling for glial fibrillary acidic protein.

[3] Conflicts of interest The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

[4] Financial disclosure The authors received no financial support for the research, authorship, and/or publication of this article.

© The Author(s) 2019 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Lara Boland, Laura Setyo, Cheryl Sangster, Laurencie Brunel, Timothy Foo, and Peter Bennett "Colonic malignant peripheral nerve sheath tumour in a cat," Journal of Feline Medicine and Surgery Open Reports 5(1), (1 January 2020). https://doi.org/10.1177/2055116919849979
Published: 1 January 2020
KEYWORDS
cyclophosphamide
metastasis
metronomic chemotherapy
Peripheral nerve sheath tumour
Back to Top